Blue Shield New Biosimilar Slash Price of Best-Selling Drug
Carrier Updates
Thursday, October 10 2024
Blue Shield of California has drastically cut the price it will pay for an FDA-approved biosimilar of blockbuster drug Humira – purchasing the medicine at a transparent net price of $525 per monthly dose, compared to the market reported net price of Humira of $2,100.1 Starting January 1, 2025, most Blue Shield commercial members will have access to this drug with $0 out of pocket cost.
These cost savings are made possible through an innovative agreement with drug manufacturer Fresenius Kabi, an operating company of Fresenius, and Evio Pharmacy Solutions, which facilitated the deal. This unique collaboration allows Blue Shield to provide members with better access to biosimilar medications with the same clinical effectiveness of a branded version at a significantly lower and transparent cost by eliminating the barriers and excessive markups often found in a traditional pharmacy benefit manager model.
To Read More Click Here
For More Information or Healp Quoting Blue Shield, Please Contact Your Dickerson Sales Rep.
These cost savings are made possible through an innovative agreement with drug manufacturer Fresenius Kabi, an operating company of Fresenius, and Evio Pharmacy Solutions, which facilitated the deal. This unique collaboration allows Blue Shield to provide members with better access to biosimilar medications with the same clinical effectiveness of a branded version at a significantly lower and transparent cost by eliminating the barriers and excessive markups often found in a traditional pharmacy benefit manager model.
To Read More Click Here
For More Information or Healp Quoting Blue Shield, Please Contact Your Dickerson Sales Rep.